A domestic death toll with a foreign policy address.

Fentanyl is synthetic. It does not require a crop, a growing season, or land. It requires precursor chemicals, most of which originate in China's chemical and pharmaceutical manufacturing sector — an industry large enough that the relevant compounds move as legitimate commercial exports.

Scheduling controls have repeatedly produced a predictable response: producers modify a molecule slightly, and the new compound falls outside the controlled list until regulators catch up. Enforcement chases a chemical definition while the industry iterates around it. That gap is a diplomatic and regulatory problem before it is a policing one, and it is negotiated — or not negotiated — at the level of US-China relations.

Precursors are shipped to Mexico, where cartel networks — principally Sinaloa and Jalisco New Generation — synthesize fentanyl and press it into counterfeit pills made to resemble prescription medication: oxycodone, Percocet, Xanax, Adderall.

Pressing is not pharmaceutical manufacturing. Dosing within a single batch is inconsistent, which is why the practical risk to a high school student is not "choosing to use fentanyl." It is taking a pill they believe is something else, from a source they believe is safe, with no way to know what is in it. That is a supply problem expressing itself as an individual-choice narrative.

Fentanyl enters the United States overwhelmingly through legal ports of entry, hidden in the enormous legitimate cargo and passenger volume that crosses the US-Mexico border every day. It is potent enough that a commercially meaningful quantity is physically small — which is precisely what makes interdiction at volume so difficult.

This puts fentanyl policy inside trade policy. Inspection capacity, scanning technology at ports of entry, customs staffing, and the terms of cooperation with both Mexico and China are the actual levers. Border rhetoric that ignores the port-of-entry reality does not move any of them.

Naloxone reverses an opioid overdose. It does not reduce supply, and it does not change a single decision made upstream. It buys back the minutes between a respiratory arrest and an ambulance. That is a bridge intervention — indispensable and insufficient at the same time.

FRI is explicit about holding both. In the room, we teach students to keep someone alive. Outside the room, we argue that a country that has to train teenagers in emergency reversal medicine has already accepted a policy failure much further up the chain. Program data is what lets us make the second argument credibly instead of rhetorically.